International Psoriasis Council

Support our work
subscribe
Covid-19 resource Center
Advancing Knowledge. Enhancing Care.
subscribe
Covid-19 resource Center

Advancing Knowledge. Enhancing Care.

WELCOME TO THE
INTERNATIONAL PSORIASIS COUNCIL

Meet Our Experts

Search IPC’s network of psoriasis experts across the globe.

Search Directory

View Upcoming Events

Take a look at upcoming IPC symposia and events.
View Events

Browse Resource Library

Learn about the latest in psoriasis research and treatment guidelines.

Search Resources
Subscribe here for home page

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.

The Latest Psoriasis News

BIOMAP Collaboration Update A Systemic Review on Biomarkers

BIOMAP Collaboration Update: A Systemic Review on Biomarkers

Annually, the IPC Board selects a specific subject of importance and commissions a group of experts to conduct a best evidence review. In 2021, IPC supported the BIOMAP collaboration to complete a systematic review on biomarkers. Last month, two new lay summaries were published by BIOMAP on this project.
Read More

U.S. Food and Drug Administration Approves Sotyktu™(deucravacitinib)

Sotyktu™(deucravacitinib), an oral treatment for adults with moderate to severe plaque psoriasis. Sotyktu™ is the only approved TYK2 inhibitor worldwide and the first improvement in oral treatment for moderate to severe plaque psoriasis in nearly ten years.
Read More
BMS Press Release Graphic
Blog - Commentary - Alexander Egeberg - graphic

Commentary: Drug Survival Associated with Effectiveness and Safety of Treatment with Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients with Psoriasis

Real-world evidence studies become crucial to achieving the evidence needed in clinical practice. But how are data evaluated in the complexity of the real world? Alexander Egeberg, MD, PhD, DMSc, discusses a present study that examined drug survival among 16,122 treatment courses of biologic therapy with either guselkumab, ixekizumab, secukinumab, ustekinumab, or adalimumab, using United Kingdom registry data.
Read More

Latest Resources

Support Our Work

We believe that psoriasis patients, no matter where they live in the world, no matter how complex their symptoms, should have access to the best care available to them. Please join us in making this possible.

Learn How